Investigational drug · Phase 3
TDF
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis, Chronic Hepatitis B Infection.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 18, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
1,324
Any phase or sponsor naming "TDF"
First trial start
2025
Jul 15, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TDF", any sponsor or status.
Conditions studied
As listed on its trial records.
- Human Immunodeficiency Virus (HIV)
- HIV Pre-Exposure Prophylaxis
- Chronic Hepatitis B Infection
Approved drugs for the same conditions: Hepatitis B · Infectious disease and vaccines · Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "TDF" as an intervention, largest first.
- Impact of Immediate Versus South African Recommendations Guided ART Initiation on HIV IncidencePivotal-lookingCompleted
ANRS, Emerging Infectious DiseasesGovernment (non-federal)
NCT01509508 · 28,153 participants · Start Mar 2012 · Primary completion Jun 2016
Drug: Immediate ARV treatment initiation with TDF/FTC/EFV · For: HIV Infection
Sites: Hlabisa, South Africa
University of WashingtonAcademic, hospital or other
NCT04666792 · 25,457 participants · Start Mar 1, 2021 · Primary completion Dec 31, 2024
Drug: PrEP · For: HIV Infections; Contraception; STI
Sites: Kisumu, Kenya
- Evaluation of PrEP-30: a Demonstration Project of Pre-exposure Prophylaxis for MSM and Other High-risk Group Clients at the Thai Red Cross Anonymous ClinicEnrolling by invitation
Thai Red Cross AIDS Research CentreAcademic, hospital or other
NCT02437981 · 20,000 participants (planned) · Start Dec 2014 · Primary completion Dec 2024
Drug: PrEP · For: HIV Prevention
Sites: Bangkok, Thailand
Huashan HospitalAcademic, hospital or other
NCT05937178 · 20,000 participants (planned) · Start Jan 31, 2023 · Primary completion Jan 31, 2029
Drug: ETV/TAF/TDF/TMF/IFN; ETV/TAF/TDF/TMF · For: Hepatitis B, Chronic
Sites: Hefei, China; Beijing, China; Chongqing, China · 44 sites in all
The First Affiliated Hospital of Zhengzhou UniversityAcademic, hospital or other
NCT07169656 · 15,000 participants (planned) · Start Jun 3, 2024 · Primary completion Jun 30, 2032
Drug: ETV,TDF,TAF,TMF; Peginterferon α-2b injection · For: Chronic Hepatitis b
Sites: Anyang, China; Guangzhou, China; Hebi, China · 162 sites in all
- Real World Study About Anti-viral Regimen Adjustment on Achieving Complete Response in CHB PatientsStatus unknown
The Second Affiliated Hospital of Chongqing Medical UniversityAcademic, hospital or other
NCT04724785 · 10,000 participants (planned) · Start Dec 1, 2020 · Primary completion Jul 1, 2022
Drug: regimen change · For: Sustained Virologic Response; Hepatitis B, Chronic
Sites: Chongqing, China
- Expanded PrEP Implementation in Communities in NSWPivotal-lookingCompleted
Kirby InstituteGovernment (non-federal)
NCT02870790 · 9,733 participants · Start Mar 2016 · Primary completion Mar 2019
Drug: TDF/FTC · For: HIV; STI
Sites: Canberra, Australia; Albury, Australia; Alexandria, Australia · 31 sites in all
- Treatment of Hepatitis B in Resource-limited Settings - a Pilot Program in East AfricaActive, not recruiting
Oslo University HospitalAcademic, hospital or other
NCT02344498 · 7,350 participants · Start Jan 2015 · Primary completion Dec 2026
Drug: Tenofovir disoproxil · For: Hepatitis B
Sites: Addis Ababa, Ethiopia
- Strengthening Hepatitis B Screening, Linkage to Care and Long-Term Monitoring in Phichit Province, Thailand: A Birth Bohort ApproachNot yet recruiting
The Task Force for Global HealthAcademic, hospital or other
NCT07258251 · 6,000 participants (planned) · Start Jan 1, 2026 · Primary completion Dec 31, 2028
Drug: Tenofovir Alafenamide (TAF) · For: Chronic Hepatitis B; Hepatitis B Virus Infection
Sites: Phichit, Thailand
Gilead SciencesGilead Sciences (GILD)
NCT02842086 · 5,399 participants · Start Sep 2, 2016 · Primary completion Jan 31, 2019
Drug: F/TAF; F/TDF and 2 more · For: Pre-Exposure Prophylaxis of HIV-1 Infection
Sites: Beverly Hills, California; Los Angeles, California; Newport Beach, California · 93 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Determinants of, and interventions to support, pharmacy professionals' research engagement: a systematic review using the Theoretical Domains Framework.
Jones C, Kenyon M, Franklin BD, et al. · Res Social Adm Pharm 2027
- Valorization of coffee silver skin and almond skin as a source of dietary fiber, phenolics, and protein in muffins.
Ahmad T, Esposito F, Rauf MA, et al. · Food Chem X 2026
- Supporting the Uptake of Evidence-Based Care for Degenerative Meniscal Tears and Early Knee Osteoarthritis: A Collaborative Approach to the Development of an Intervention Using Stakeholder Perspectives and Integrating Behaviour Change Theory.
O'Leary H, Toomey E, French HP, et al. · Health Expect 2026
- Community pharmacists' views on the factors influencing prescription medication side effect counselling: a qualitative interview study.
Evrard P, Crowley M, Otway T, et al. · Int J Clin Pharm 2026
- Perspectives of women and healthcare providers on facilitators and barriers to cervical cancer screening in the rural Kilimanjaro region Tanzania: a qualitative study.
Machange RF, Njau B, Mtuya CC, et al. · Glob Health Action 2026
- Committing to oral care support for older people living in long-term residential care settings: A theoretically informed scoping review of enablers and barriers influencing care staff behaviours.
Spilsbury K, Csikar J, Devi R, et al. · Int J Nurs Stud Adv 2026
Also in development for Human Immunodeficiency Virus (HIV)
- AlimatravirMK-8527Phase 34 trials
Merck & Co. · Human Immunodeficiency Virus (HIV), HIV Pre-Exposure Prophylaxis, HIV
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Merck & Co..
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.